Literature DB >> 22806699

[Local and systemic bone effects of rheumatoid arthritis].

M Rauner1, L C Hofbauer, M Aringer.   

Abstract

Rheumatoid arthritis (RA) is a bone-destructive disease that is a serious risk factor for the development of osteoporosis, which is defined by a loss in bone quality and an increased fracture risk. The proinflammatory cytokines tumor necrosis factor-α (TNFα), interleukin-6 (IL-6) and IL-17, in particular, contribute to local and systemic bone loss in RA. While effectively reducing inflammation, glucocorticoids add to the fracture risk. Therefore, an adequate supply of calcium and vitamin D is essential. For many patients with RA, bone density measurements are recommended.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806699     DOI: 10.1007/s00393-011-0927-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  50 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice.

Authors:  M C van der Goes; J W G Jacobs; M Boers; T Andrews; M A M Blom-Bakkers; F Buttgereit; N Caeyers; M Cutolo; J A P Da Silva; L Guillevin; J R Kirwan; J Rovensky; G Severijns; S Webber; R Westhovens; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2010-08-06       Impact factor: 19.103

Review 3.  TNF and bone.

Authors:  Jean-Pierre David; Georg Schett
Journal:  Curr Dir Autoimmun       Date:  2010-02-18

4.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

5.  Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome.

Authors:  P J Meunier; D W Dempster; C Edouard; M C Chapuy; M Arlot; S Charhon
Journal:  Adv Exp Med Biol       Date:  1984       Impact factor: 2.622

6.  Osteoclasts are essential for TNF-alpha-mediated joint destruction.

Authors:  Kurt Redlich; Silvia Hayer; Romeo Ricci; Jean-Pierre David; Makiyeh Tohidast-Akrad; George Kollias; Günter Steiner; Josef S Smolen; Erwin F Wagner; Georg Schett
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

7.  Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells.

Authors:  Martina Rauner; Claudia Goettsch; Nicola Stein; Sylvia Thiele; Martin Bornhaeuser; Karolien De Bosscher; Guy Haegeman; Jan Tuckermann; Lorenz C Hofbauer
Journal:  Endocrinology       Date:  2010-11-17       Impact factor: 4.736

Review 8.  Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.

Authors:  C B Confavreux; R D Chapurlat
Journal:  Osteoporos Int       Date:  2010-10-20       Impact factor: 4.507

9.  Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

Authors:  E Keystone; P Emery; C G Peterfy; P P Tak; S Cohen; M C Genovese; M Dougados; G R Burmester; M Greenwald; T K Kvien; S Williams; D Hagerty; M W Cravets; T Shaw
Journal:  Ann Rheum Dis       Date:  2008-04-03       Impact factor: 19.103

10.  Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.

Authors:  Robin K Dore; Stanley B Cohen; Nancy E Lane; William Palmer; William Shergy; Lifen Zhou; Huei Wang; Wayne Tsuji; Richard Newmark
Journal:  Ann Rheum Dis       Date:  2009-09-03       Impact factor: 19.103

View more
  1 in total

1.  [Multimorbidity in elderly rheumatic patients part 1].

Authors:  H-J Lakomek; T Brabant; M Lakomek; D Lüttje
Journal:  Z Rheumatol       Date:  2013-08       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.